Live Breaking News & Updates on ஹண்டிங்டன் கிழக்கு உயர் பள்ளி
Stay updated with breaking news from ஹண்டிங்டன் கிழக்கு உயர் பள்ளி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Companies attempt to dismiss opioid lawsuit rejected in WVa April 1, 2021 FacebookTwitterEmail CHARLESTON, W.Va. (AP) Three drug distributors have been denied a request for summary judgment in a lawsuit filed in West Virginia by the city of Huntington and Cabell County over the opioid crisis. U.S. District Judge David Faber on Wednesday rejected the companies attempt to dismiss the case. The trial is set to start May 3 in Charleston. The lawsuit accuses drug distributors AmerisourceBergen, Cardinal Health and McKesson of fueling the local opioid epidemic. The repeated attempts by the Big Three distributors to delay their courtroom reckoning will not deter these communities from pursuing the resources they need now to combat the opioid crisis that has only worsened amid the COVID-19 pandemic,” plaintiffs attorneys Paul Farrell Jr. and Anne Kearse said in a statement. ....
Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington s disease Alchemab using unique approach to explore adaptive immunity identifying naturally protective antibodies in resilient patients to specific diseases Innovate UK Grant to support the finding of a disease-modifying therapy for Huntington s disease (HD), a degenerative disease with no cure and no therapies to prevent progression Alchemab is working in collaboration with Medicines Discovery Catapult, a not-for-profit, government-funded organisation supporting UK life science innovators HD samples being supplied by CHDI Foundation Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington s diseas ....